But if one or a few come up with approved cell therapies for COVID-19 it’ll likely be positively transforming for them and more importantly, potentially help a lot of people. I expect some will go way back down when the biotech COVID bounce fades.
It’s a risky area as the odds are that most cell therapy companies are not going to come up with successful COVID-19 treatments. I guess they’re rolling the dice that some of these firms will develop safe and effective COVID treatments based on cells. Their stocks have zoomed in some cases as investors have been snapping them up. The pandemic has been awful to put it mildly, but it has been an opportunity for many cell therapy biotechs. COVID bounce to cell therapy & stem cell stocks There have been some name changes too, making things somewhat confusing in certain cases. We’ve also seen quite a few acquisitions of cell therapy companies in the past 2 years including Celgene and others. It seems likely that they may do IPOs in coming years. Note that some of the cell therapy biotechs that I’m featuring here are not yet publicly traded, but they are particularly interesting so I’ve decided to include them. So far in 2022, it’s been generally a pretty bad year for stem cell stocks too just as in 2021, which I detail below in a breakdown of results for 2021. Which ones might be acquisition targets? What about the impact of the FDA? How has COVID impacted them? Mostly in very positive, even if likely transient ways. Today I’m highlighting 24 “stem cell stocks”. It is definitely the case in the volatile stem cell and cell therapy arena.
This is kind of the standard of “life” as any biotech company. These biotechs have ups and downs, sometimes at the same time. I also am providing links and other info. In today’s post I go over some of the considerations for 24 stem cell and cell therapy firms. Investing in stem cell stocks is not for the timid. Till at the University of Toronto in the 1960s.Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Research into stem cells grew out of findings by Ernest A. Embryonic cell lines and autologous embryonic stem cells generated through somatic cell nuclear transfer or dedifferentiation have also been proposed as promising candidates for future therapies. Stem cells can now be artificially grown and transformed (differentiated) into specialized cell types with characteristics consistent with cells of various tissues such as muscles or nerves. By definition, autologous cells are obtained from one's own body, just as one may bank his or her own blood for elective surgical procedures.Īdult stem cells are frequently used in various medical therapies (e.g., bone marrow transplantation). Of all stem cell types, autologous harvesting involves the least risk. Stem cells can also be taken from umbilical cord blood just after birth. There are three known accessible sources of autologous adult stem cells in humans:īone marrow, adipose tissue, and blood. In a developing embryo, stem cells can differentiate into all the specialized cells-ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)-but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. Stem cells are cells that can differentiate into other types of cells, and can also divide in self-renewal to produce more of the same type of stem cells.
0 kommentar(er)
